Compounded Semaglutide vs Ozempic: 7 Real Differences
Introduction
Ozempic® is Novo Nordisk’s brand-name semaglutide injection approved by the FDA in December 2017 for type 2 diabetes. Compounded semaglutide is the same active drug substance prepared by a licensed compounding pharmacy, usually as a custom-dose vial. The drug is identical at the molecular level. Everything around it is different.
People shopping for cheaper GLP-1 access keep asking the same question: is the compounded version the same thing? The honest answer is yes and no. The semaglutide peptide that activates the GLP-1 receptor is the same molecule. The container, the dosing approach, the FDA status, and the supply chain are not. Those differences change cost, access, and risk in real ways.
This guide pulls apart seven specific differences that affect what you pay, what you inject, and what protections you get when something goes wrong.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
What Is the Actual Molecule in Each One?
Both products deliver semaglutide, a long-acting GLP-1 receptor agonist with a 165-hour half-life. Novo Nordisk holds the patent on Ozempic’s manufacturing process, not the molecule itself in every form. Compounding pharmacies source the semaglutide active pharmaceutical ingredient from FDA-registered API manufacturers, then mix it with bacteriostatic water or sterile saline plus a preservative.
Quick Answer: Ozempic and compounded semaglutide use the identical semaglutide peptide, first studied in the SUSTAIN trials and STEP 1 (Wilding et al. 2021 NEJM)
The semaglutide peptide sequence is public. The SUSTAIN program ran across SUSTAIN 1 through SUSTAIN 10, all using the same molecule that Novo Nordisk eventually commercialized. The compounded versions sold through US telehealth platforms in 2024 and 2025 used semaglutide sodium or semaglutide base salts sourced from registered API suppliers. The FDA flagged concerns about salt forms (semaglutide sodium and semaglutide acetate) as different from the approved Ozempic ingredient.
If your compounded formula uses semaglutide base in a sterile vial from a 503B outsourcing facility, you’re getting the same molecule. If a pharmacy uses a non-approved salt form, that’s a separate quality question.
How Does the Price Actually Compare?
Ozempic’s US list price was $968.52 per month in 2024 per Novo Nordisk’s published pricing. With commercial insurance and the manufacturer savings card, eligible patients can pay as little as $25 per month. Without coverage, retail cash price runs $900 to $1,000 monthly.
Compounded semaglutide through US telehealth ran $199 to $399 per month across major platforms in 2024 and 2025. Some offered intro pricing as low as $149 per month at lower doses. The price gap reflects the absence of brand markup and the compounded product’s exemption from PBM rebate structures. It’s also why compounded grew so fast during the official semaglutide shortage from May 2022 to February 2025.
Insurance does not cover compounded versions. You pay cash. For someone without GLP-1 coverage, compounded is often four to five times cheaper than retail Ozempic.
Why Is Ozempic FDA-approved but Compounded Is Not?
Ozempic went through full FDA approval in 2017 with NDA 209637, backed by the SUSTAIN trial program. The agency reviewed manufacturing, safety, and efficacy data. Novo Nordisk reports adverse events through the FDA’s MedWatch system. The product gets full post-market surveillance.
Compounded drugs are legal under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. 503A applies to pharmacies that compound for individual patients with valid prescriptions. 503B covers outsourcing facilities that produce larger batches under cGMP-lite standards. Neither requires FDA approval of the finished product. Both must use bulk drug substances that meet specific criteria, which is where compounded GLP-1s have faced the most regulatory friction.
During an FDA-declared shortage, 503B outsourcing facilities can compound a copy of a commercial drug. The semaglutide shortage was declared in May 2022. The FDA removed semaglutide from the shortage list in February 2025, ending that legal lane for mass 503B production of compounded semaglutide copies.
How Does Dosing Differ Between the Two?
Ozempic comes in prefilled multi-dose pens at four fixed strengths: 0.25 mg, 0.5 mg, 1 mg, and 2 mg per weekly injection. You dial the pen to the prescribed dose. You can’t fine-tune between those steps.
Compounded semaglutide ships in a vial. Your provider writes a dose in milligrams or units. Typical compounded titration starts at 0.25 mg weekly for four weeks, increases to 0.5 mg for four weeks, then to 1 mg, with custom steps in between if needed. Some patients hold at 0.7 mg or 1.2 mg, doses Ozempic doesn’t offer. That flexibility helps if side effects flare at standard step-ups.
The trade-off is user error. With a vial and syringe, you draw the dose yourself. A miscount of units in a U-100 syringe can mean a 4x dose. With Ozempic’s pen, the device meters the dose for you. STEP 1 (Wilding et al. 2021 NEJM) used 2.4 mg as the obesity dose, which Ozempic doesn’t offer in the US (that’s the Wegovy® dose).
What About Ingredients Besides Semaglutide?
Ozempic’s inactive ingredients are disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. Nothing else.
Many compounded versions add vitamin B12 (cyanocobalamin) or B6. Vendors pitch this as a nausea-reduction aid or energy support. There’s no strong trial evidence that B12 in injectable semaglutide reduces side effects. The FDA specifically called out concerns about adding ingredients to compounded GLP-1s because each addition changes the stability and sterility profile of the compound.
Some compounded formulations also vary the preservative or buffer. If you’re allergic to any inactive ingredient, the compounded formula list matters as much as the active drug. Ask for the full ingredient sheet before injecting.
Key Takeaway: Ozempic ships in fixed-dose prefilled pens (0.25, 0.5, 1, 2 mg); compounded comes in multi-dose vials with custom titration
Which One Has More Clinical Trial Data Behind It?
Ozempic has the SUSTAIN program (10 trials), the SELECT cardiovascular outcomes trial (Lincoff et al. 2023 NEJM, 17,604 patients, 20% MACE reduction), the FLOW kidney trial (Perkovic et al. 2024 NEJM, 24% reduction in major kidney/CV death), and the STEP-HFpEF heart failure trial. Tens of thousands of patient-years of randomized data exist on semaglutide as a molecule.
Compounded semaglutide has zero head-to-head randomized trials against Ozempic. Vendors cite the trial data on the brand product as evidence for their compound, on the logic that it’s the same molecule. That’s a reasonable inference if (and only if) the compounded product actually delivers the same drug at the same potency. Some independent USP testing has found variability in semaglutide content across compounded samples.
If you choose compounded, you’re inheriting the brand’s clinical evidence on faith that what you’re injecting matches what Novo Nordisk made. Pharmacy quality matters a lot here.
Who Regulates the Compounded Product?
503A pharmacies are licensed by state boards of pharmacy. State boards inspect them, set scope-of-practice rules, and discipline bad actors. The FDA has limited direct authority over 503A unless the pharmacy ships across state lines in bulk or violates federal standards. 503B outsourcing facilities register directly with the FDA and follow cGMP-lite standards, with regular FDA inspections.
The 503A versus 503B distinction matters for risk. A reputable 503B outsourcing facility undergoes FDA inspection and follows batch-record requirements close to a manufacturer. A 503A pharmacy compounding for individual patients has less oversight, more flexibility, and more variability. Both are legal lanes, but they differ in quality controls.
When TrimRx works with compounding partners, the question to ask is which lane the pharmacy operates in and what third-party potency and sterility testing the finished product undergoes. A free assessment quiz on a telehealth platform doesn’t tell you which pharmacy ships the drug. Ask directly.
How Did the FDA Shortage Ruling Change Things?
In May 2022, the FDA declared semaglutide in shortage, which opened the 503B lane for compounded copies. That ruling fueled the explosion of compounded semaglutide telehealth from 2022 to 2024. In October 2024, the FDA initially announced the shortage was resolved, then reversed under court pressure. In February 2025, the agency finalized that the shortage had ended.
After the shortage ended, 503B outsourcing facilities lost the legal basis for compounding copies of Ozempic. 503A pharmacies can still compound semaglutide for individual patients with valid prescriptions, but the formula must be clinically different from the commercial product (different dose, different ingredients, or documented clinical need).
This is why compounded semaglutide didn’t disappear in 2025. It shifted to 503A pathways with personalized dosing or added ingredients. The compliance question every buyer should ask is whether the formula is genuinely personalized or whether the pharmacy is skating on a thin clinical justification.
Which One Is Right for You?
If you have type 2 diabetes and insurance coverage for Ozempic, the brand is straightforward: covered, FDA-approved, pen-delivered, no questions about potency. If you have obesity (BMI 30+, or 27+ with comorbidity), Wegovy is the labeled brand product, not Ozempic.
If you’re paying cash and have no GLP-1 coverage, compounded semaglutide through a legitimate 503A pharmacy with third-party testing can cut your cost by 60% to 80%. The risk is real but quantifiable. The bigger risk is sourcing from an unvetted online vendor with no pharmacy license. TrimRx’s personalized treatment plan walks through which pathway fits your insurance situation and clinical profile.
Bottom line: The FDA ended the semaglutide shortage in February 2025, narrowing the legal lane for mass 503B compounding
FAQ
Is Compounded Semaglutide the Same as Ozempic?
The active drug is the same molecule, semaglutide. The product is not the same. Ozempic is an FDA-approved branded injection from Novo Nordisk in a prefilled pen. Compounded semaglutide is a pharmacy-prepared vial without FDA approval, sometimes with added ingredients like B12.
Can I Get the Same Weight Loss Results with Compounded Semaglutide?
If the compounded product delivers the same semaglutide at the same dose, the trial data on Ozempic (and on Wegovy at 2.4 mg, per STEP 1 Wilding et al. 2021 NEJM showing 14.9% weight loss) supports similar outcomes. Real-world results depend on pharmacy quality and dose accuracy.
Is Compounded Semaglutide Legal in 2026?
Yes, under section 503A of the FDCA, with a valid prescription. The FDA ended the semaglutide shortage in February 2025, which closed the 503B mass-compounding lane. 503A personalized compounding remains legal but must reflect a genuine clinical need.
Why Is Ozempic So Much More Expensive?
Ozempic’s $968 monthly list price covers Novo Nordisk’s R&D recovery, FDA approval costs, marketing, and PBM rebates. Compounded versions skip all of that. The actual API cost for semaglutide is a small fraction of either price.
Does Insurance Cover Compounded Semaglutide?
Almost never. Commercial insurance and Medicare don’t reimburse compounded GLP-1s. Patients pay cash. That’s why compounded telehealth pricing of $200 to $400 monthly competes with $968 retail Ozempic.
Can I Switch From Ozempic to Compounded Semaglutide?
Yes, with provider guidance. Most clinicians match your current Ozempic dose in mg per week when transitioning to compounded vials. Side effects shouldn’t change much if the dose is matched. Watch for early-week injection-site or GI symptoms that signal a potency mismatch.
Is There Any Safety Advantage to Staying on Brand Ozempic?
Yes, in three ways: dose accuracy from a metered pen, FDA-overseen manufacturing, and clear adverse-event reporting through MedWatch. Compounded products lack all three protections unless the pharmacy publishes third-party testing.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
Semaglutide for Seniors: Safety, Dosing, and What to Expect
Adults 65 and older are one of the fastest-growing groups seeking GLP-1 medications, and for good reason. Obesity in older adults is associated with…
Can You Take Semaglutide Forever? What Long-Term Use Looks Like
It’s one of the most common questions patients ask once semaglutide starts working: do I have to stay on this forever? The question cuts…
Why Compounded Semaglutide Is Cheaper Than Brand
Compounded semaglutide costs less than Ozempic and Wegovy because the pricing covers different things.
